Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo/Immunotherapy in Performance Status 2 vs 0-1 NSCLC Patients
NCT04253964Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2020
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, atezolizumab and cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Progression-Free Survival at 12 weeks. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04253964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253964.